Understanding CGRP and cardiovascular risk

Eloísa Rubio-Beltrán, Antoinette Maassen van den Brink*

*Corresponding author for this work

Research output: Chapter in Book/Report/Conference proceedingChapterpeer-review

14 Citations (Scopus)

Abstract

Increasing knowledge about the role of calcitonin gene-related peptide (CGRP) in migraine pathophysiology has led to the development of antibodies against this peptide or its receptor. However, CGRP is widely expressed throughout the body, participating not only in pathophysiological conditions but also in several physiological processes and homeostatic responses during pathophysiological events. Therefore, in this chapter, the risks of long-term blockade of the CGRP pathway will be discussed, with focus on the cardiovascular system, as this peptide has been described to have a protective role during ischemic events, and migraine patients present a higher risk of stroke and myocardial infarction.

Original languageEnglish
Title of host publicationHandbook of Experimental Pharmacology
PublisherSpringer New York LLC
Pages131-140
Number of pages10
DOIs
Publication statusPublished - 2019

Publication series

NameHandbook of Experimental Pharmacology
Volume255
ISSN (Print)0171-2004
ISSN (Electronic)1865-0325

Keywords

  • Cardiovascular safety
  • CGRP
  • CGRP (receptor) antibodies
  • Migraine
  • Myocardial infarction
  • Stroke

Fingerprint

Dive into the research topics of 'Understanding CGRP and cardiovascular risk'. Together they form a unique fingerprint.

Cite this